WHO Nations Wrestle Over Who Owns a Pandemic's Most Valuable Resource

When a novel pathogen emerges, the first thing scientists race to collect is not a vaccine or a treatment. It is the virus itself. Whoever shares that biological material earliest shapes the entire global response, and for decades, the question of what poorer nations receive in return has gone largely unanswered. That negotiating gap is precisely what brought WHO member states back to the table in Geneva from February 9 through 14, 2026, for the fifth round of talks on the Pathogen Access and Benefit Sharing annex, the most contested piece of the broader WHO Pandemic Agreement.

The Intergovernmental Working Group, established by the World Health Assembly specifically to hammer out this annex, spent the week navigating a tension that has quietly defined global health diplomacy for years. Low and middle-income countries, many of which sit at the geographic frontlines of zoonotic spillover events, have long argued that they share pathogen samples with international laboratories and receive little in return when those samples become the foundation for commercially lucrative vaccines and diagnostics. High-income countries and pharmaceutical industry stakeholders, meanwhile, worry that overly restrictive benefit-sharing requirements could slow the speed of outbreak response at precisely the moment when speed is everything.

The PABS framework is designed to resolve that standoff by creating a formal system under which countries contribute biological materials to a shared pool and, in exchange, receive guaranteed access to the medical countermeasures those materials help produce. In theory, it is an elegant solution. In practice, the details are ferociously difficult. How are benefits calculated? Who verifies compliance? What happens when a private company, rather than a public institution, develops the product downstream?

The PABS negotiations do not exist in a vacuum. They sit awkwardly alongside the Nagoya Protocol, a 2010 agreement under the Convention on Biological Diversity that governs access to genetic resources more broadly. For years, there has been a legal ambiguity about whether pathogen genetic sequences, especially digital sequence information shared through databases like GISAID, fall under Nagoya's jurisdiction or outside it. The WHO process is partly an attempt to create a health-specific lane that moves faster and with clearer pandemic-response incentives than the broader biodiversity framework allows.

That jurisdictional complexity matters because it shapes the incentives of every actor at the table. A country that believes it can leverage Nagoya protections independently has less reason to make concessions inside the WHO process. A pharmaceutical company operating across multiple regulatory environments needs legal certainty before it will commit to benefit-sharing obligations that could affect its pricing and licensing strategies. The fifth IGWG meeting, by all accounts, made progress in narrowing some of these gaps, though the WHO described the discussions as productive without releasing specific compromise language.

What makes this round of talks particularly significant is the timeline pressure bearing down on it. The broader WHO Pandemic Agreement, adopted in principle after years of post-COVID negotiations, needs its PABS annex to function as anything more than a framework document. Without a workable system for pathogen sharing and benefit distribution, the agreement risks becoming a diplomatic achievement that dissolves at the first real test.

The systems-level consequence that rarely surfaces in coverage of these talks is what happens to pathogen surveillance if the PABS framework fails or stalls. Countries that feel exploited by the current informal system have a rational incentive to delay sharing samples, to share less complete data, or to conduct more sequencing domestically before releasing anything internationally. That behavioral response, entirely predictable from a game-theory standpoint, is arguably more dangerous than any single policy failure. A world in which outbreak data moves slowly because trust has broken down is a world in which the early warning window that determines pandemic trajectories gets shorter with every emerging threat.

The February negotiations represent one more attempt to build the kind of reciprocal trust that makes rapid sharing feel rational rather than naive. Whether the annex that eventually emerges can actually deliver that trust, across governments, companies, and scientific institutions with genuinely different interests, will determine not just the fate of one WHO agreement but the operating logic of global health security for the next generation of outbreaks.

The next meeting of the working group has not yet been publicly scheduled, but with the World Health Assembly convening in May, the pressure to arrive with something concrete is only going to intensify.